Remission of Systemic Lupus Erythematosus

Medicine

Volumn 75, Issue 2, 1996, Pages 88-98

  Drenkard, Cristina ^a   Villa, Antonio R ^a   García Padilla, Carlos ^a   Pérez Vázquez, María Esther ^a   Alarcón Segovia, Donato ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CHLOROQUINE; COMPLEMENT COMPONENT C3; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DNA ANTIBODY; DOUBLE STRANDED DNA; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; VALPROIC ACID; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; STEROID;

ADULT; ARTHRALGIA; CASE REPORT; CHILD; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HEMOLYTIC ANEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LEUKOPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; REVIEW; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT OUTCOME; ARTICLE; DRUG COMBINATION; FOLLOW UP; MORTALITY; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TIME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; CHILD; CHLOROQUINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; STEROIDS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030094505     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-199603000-00005     Document Type: Article

References (33)

1. Alarcón-Segovia D, Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 21: 275-86, 1992.
2. Alcocer-Varela J, Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 69: 1388-92, 1982.
3. Alvarado C, Alcocer-Varela J, Llorente L, Richaud-Patin I, Cerbon M, Alarcón-Segovia D. Effect of CD28 antibody on T cells from patients with systemic lupus erythematosus. J Autoimmunity 7: 763-73, 1994.
4. Cox DR. Regression models and life tables. J R Stat Soc 34: 187-203, 1972.
5. Drenkard C, Villa AR, Alarcón-Segovia D, Pérez-Vázquez ME. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 21: 1067-72, 1994.
6. Dubois EL. The effect of the L.E. Cell Test on the clinical picture of systemic lupus erythematosus. Ann Intern Med 38: 1265-94, 1953.
7. Dubois EL. Systemic lupus erythematosus: Recent advances in its diagnosis and treatment. Ann Intern Med 45: 163-84, 1956.
8. EGRET v 0.25.1. Statistics and Epidemiology Research Corporation. Seattle, Wa.
9. Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore) 50: 85-95, 1971.
10. Euler HH, Schroeder JO, Harten P, Zeuner RA, Gutschmidt HJ. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 37: 1784-94, 1994.
11. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: Diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore) 55: 323-39, 1976.
12. Fries JF, Holman HR. In: Smith LH Jr, ed. Systemic lupus erythematosus: A clinical analysis. Vol. VI. Philadelphia: WB Saunders, pp. 127-33, 1975.
13. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus. A discordance between clinical and serologic features. Am J Med 66: 210-15, 1979.
14. Guzmán J, Cardiel MH, Arce-Salinas A, Sánchez-Guerrero J, Alarcón-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 19: 1551-58, 1992.
15. Halberg P, Alsbjorn B, Trolle Balslov J, Gerstoft J, Lorenzen I, Ullman S, Wiik A. Systemic lupus erythematosus: Follow-up study of 148 patients. I: Classification, clinical and laboratory findings, course and outcome. Clin Rheumatol 6: 13-21, 1987.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-81, 1958.
17. Kovacs JAJ, Urowitz MB, Gladman DF. Dilemmas in neuropsychiatric lupus. Rheum Dis Clin North Am 19: 795-814, 1994.
18. Laffón A, Alcocer-Varela J, Alarcón-Segovia D. Differences in the kinetics of the autologous mixed lymphocyte reaction between the various connective tissue diseases. Rheumatol Int 3: 117-28, 1983.
19. Lee P, Urowitz MB, Bookman AAM, Koehler BE, Smythe HA, Gordon DA, Ogryzlo MA. Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 46: 1-32, 1977.
20. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six system for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32: 1107-18, 1989.
21. López-Karpovich X, Cardiel M, Cárdenas R, Piedras J, Alarcón-Segovia D. Circulating colony-forming units of granulocytes and monocytes/ macrophages in systemic lupus erythematosus. Clin Exp Immunol 77: 43-46, 1989.
22. Melendro EI, Saldate C, Rivero SJ, Alarcón-Segovia D. T-Cell subpopulations in the peripheral blood of patients with connective tissue diseases as determined by flow cytometry using monoclonal antibodies. Clin Immunol Immunopathol 27: 340-47, 1983.
23. Rivero SJ, Díaz-Jouanen E, Alarcón-Segovia D. Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance. Arthritis Rheum 21: 295-305, 1978.
24. Ropes MW. Observations on the natural course of disseminated lupus erythematosus. Medicine (Baltimore) 43: 387-91, 1964.
25. Sergent JS, Lockshin MD, Klempner MS, Lipsky BA. Central nervous system disease in systemic lupus erythematosus. Therapy and prognosis. Am J Med 58: 644-54, 1975.
26. Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 19: 47-52, 1992.
27. SPSS/PC+ v 5.0 Chicsgo, Ill.
28. Swaak AJG, Nossent JC, Bronsveld W, Van Rooyen A, Nieuwenhuys EJ, Theuns L, Smeenk RJT. Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 48: 477-54, 1989.
29. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-77, 1982.
30. Tozman ECS, Urowitz MB, Gladman DD. Prolonged complete remission in previously severe SLE. Ann Rheum Dis 41: 39-40, 1982.
31. Tumulty PA. The clinical course of systemic lupus erythematosus. JAMA 156: 947-53, 1954.
32. Walz LeBlanc BAE, Urowitz MB, Gladman DD. Serologically active, clinically quiescent systemic lupus erythematosus. Longterm followup. J Rheumatol 21: 174-75, 1994.
33. Zeldis A. Curación en el lupus eritematoso sistémico. Rev Med Chil 92: 299-301, 1964.